In the language of visionary decks, The Lovers symbolizes the power of two distinct forces—structured and fluid—working in perfect resonance to create new potential.
PAIR embodies that same precision harmony in pharmacology. One steadfast NSAID delivers disciplined control of COX-driven inflammation. One finely tuned mast-cell modulator calms the immune system’s earliest ignition—addressing inflammation upstream, comprehensively, and without suppression while proactively protecting against GI, renal and other NSAID-induced injury .
Together, they form a new choreography: moving in concert to intercept the first flare of inflammation before it can scar tissue, degrade cognition, drive disease, or accelerate aging. Rather than forcing the body into submission, PAIR guides it back toward its natural equilibrium.
This revolutionary mechanism powers a growing portfolio—11 unique therapeutics spanning eight major therapeutic arenas. From OTC Metabolic Recovery and Common Cold care to Prescription-strength interventions for Opioid Withdrawal, Hospital Runaway Inflammation Rescue, Arthritis, Vaccine Side-Effect Relief, Anti-Aging, and more.
Each asset is a precisely calibrated variation—adjusting dose, ratio, and delivery to let PAIR’s synergy achieve targeted, tissue-protective outcomes across diverse indications. And because these molecules bring decades of proven safety, the platform delivers multi-pathway, pleiotropic power with minimal side effects—a scalable, affordable arsenal of anti-inflammatories the world urgently needs.
If stem cells are the body’s architects of regeneration, mast cells are its master regulators of immune response. Both operate upstream—shaping outcomes long before symptoms appear.
Mast cells are distributed throughout the body, acting as sentinels that detect tissue stress and initiate protective responses. When activated appropriately, they help orchestrate healing—releasing signals that defend and repair.
But under sustained stress, metabolic dysfunction, or toxic overload, these same mechanisms can misfire—triggering cascades of histamines, cytokines, and proteases that cause lasting tissue damage and drive the progression of chronic disease.
In this way, mast cells are not peripheral players. They sit at the root of inflammatory control—often determining whether the body restores balance or tips into a cycle of escalating damage.
PAIR intervenes at this pivotal upstream point—not to silence mast cells, but to guide them. By modulating their earliest activity—while a complementary NSAID tempers COX-driven amplification—PAIR reshapes the entire inflammatory cascade.
The result: faster resolution, preserved tissue integrity, and a rebalanced immune response—moving the body toward healing rather than harm.
Every therapeutic in our pipeline builds upon this unified insight: that by engaging mast cells with precision, we can intercept inflammation at its root across a wide range of diseases
Next, see how this approach powers distinct programs—each tuning the core PAIR duet to deliver targeted, realworld impact.
A night of cocktails or an oversized plate triggers the same underlying
metabolic stress: insulin spikes, gut permeability, and histamine-fueled
inflammation. SJP-001 is designed to intervene upstream—combining a fast acting NSAID with our mast-cell modulator to modulate this inflammatory
surge.
Our goal: to support the body’s return to metabolic balance, cognitive clarity,
and improved next-day function after episodes of dietary or alcohol-related
overload.
Opioid withdrawal triggers a surge of mast-cell-driven pain, gut distress, and anxiety – factors that often drive relapse and undermine recovery efforts. SJP-005 offers a novel, non-opioid approach, designed to modulate the inflammatory rebound that underlies many withdrawal symptoms.
Our work on SJP-005 has attracted the attention of the National Institute for Drug Abuse (NIDA), which is now supporting the advancement of this critical program through ongoing clinical development.
(PAIR Injectable for Hospital Settings)
When infection, trauma, or surgery triggers systemic inflammatory response, rapid intervention is essential. SJP-100 is engineered for fast deployment—IV—inside critical-care settings. By targeting upstream mast-cell activity, it aims to modulate the cytokine cascades that contribute to sepsis, ARDS, and multi-organ dysfunction.
The vision: to help reduce ICU stays, ventilator dependence, and organ injury—offering a scalable, immune-sparing alternative to high-cost biologics for inflammatory crisis management.
Upper-respiratory infections are the world’s most common illness —and can escalate to life-threatening outcomes when inflammatory cascades damage lung tissue. SJP-002C/002 is designed to intervene upstream, pairing mast-cell modulation with antiviral action to help modulate the immune response and protect respiratory function.
SJP-002C has successfully completed Phase 2 clinical trials with promising results and is advancing toward further development.
At Sen-Jam, our passion for health doesn’t stop with humans. We’re exploring how our proprietary inflammation modulation technology may support veterinary therapeutics — from household pets to performance animals.
It’s early, but promising. As our scientific journey grows, do does our potential to impact the well-being of animals who move us, serve us and heal us in return.
The Sen-Jam founders with their beloved pups, and Partner Christine Leonard with her equine companion.
Every therapeutic program in our portfolio draws from the same powerful duet—an NSAID and a mast-cell modulator—but each is precisely calibrated to meet the unique demands of its target condition. By soothing the earliest spark of inflammation before it cascades into damage, PAIR preserves tissue, time, and quality of life.
If advancing health by design—not chasing it in decline—aligns with your mission, let’s compare notes.